T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial
dc.rights.license | open | en_US |
hal.structure.identifier | Statistics In System biology and Translational Medicine [SISTM] | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | RICHERT, Laura | |
dc.contributor.author | LELIEVRE, Jean Daniel | |
dc.contributor.author | LACABARATZ, Christine | |
hal.structure.identifier | Statistics In System biology and Translational Medicine [SISTM] | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | HARDEL, Lucile | |
dc.contributor.author | HOCINI, Hakim | |
dc.contributor.author | WIEDEMANN, Aurelie | |
dc.contributor.author | LUCHT, Frederic | |
dc.contributor.author | POIZOT-MARTIN, Isabelle | |
hal.structure.identifier | Statistics In System biology and Translational Medicine [SISTM] | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | BAUDUIN, Claire | |
dc.contributor.author | DIALLO, Alpha | |
dc.contributor.author | RIEUX, Veronique | |
hal.structure.identifier | Statistics In System biology and Translational Medicine [SISTM] | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | ROUCH, Elodie | |
dc.contributor.author | SURENAUD, Mathieu | |
dc.contributor.author | LEFEBVRE, Cecile | |
dc.contributor.author | FOUCAT, Emile | |
dc.contributor.author | TISSERAND, Pascaline | |
dc.contributor.author | GUILLAUMAT, Lydia | |
hal.structure.identifier | Statistics In System biology and Translational Medicine [SISTM] | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | DURAND, Melany | |
hal.structure.identifier | Statistics In System biology and Translational Medicine [SISTM] | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | HEJBLUM, Boris | |
dc.contributor.author | LAUNAY, Odile | |
hal.structure.identifier | Statistics In System biology and Translational Medicine [SISTM] | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | THIEBAUT, Rodolphe | |
dc.contributor.author | LEVY, Yves | |
dc.date.accessioned | 2023-03-13T14:39:02Z | |
dc.date.available | 2023-03-13T14:39:02Z | |
dc.date.issued | 2022-06-15 | |
dc.identifier.issn | 0022-1767 | en_US |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/172274 | |
dc.description.abstractEn | Heterologous prime-boost strategies are of interest for HIV vaccine development. The order of prime-boost components could be important for the induction of T cell responses. In this phase I/II multi-arm trial, three vaccine candidates were used as prime or boost: modified vaccinia Ankara (MVA) HIV-B (coding for Gag, Pol, Nef); HIV LIPO-5 (five lipopeptides from Gag, Pol, Nef); DNA GTU-MultiHIV B (coding for Rev, Nef, Tat, Gag, Env gp160 clade B). Healthy human volunteers (n = 92) were randomized to four groups: 1) MVA at weeks 0/8 + LIPO-5 at weeks 20/28 (M/L); 2) LIPO-5 at weeks 0/8 + MVA at weeks 20/28 (L/M); 3) DNA at weeks 0/4/12 + LIPO-5 at weeks 20/28 (G/L); 4) DNA at weeks 0/4/12 + MVA at weeks 20/28 (G/M). The frequency of IFN-γ–ELISPOT responders at week 30 was 33, 43, 0, and 74%, respectively. Only MVA-receiving groups were further analyzed (n = 62). Frequency of HIV-specific cytokine-positive (IFN-γ, IL-2, or TNF-α) CD4+ T cells increased significantly from week 0 to week 30 (median change of 0.06, 0.11, and 0.10% for M/L, L/M, and G/M, respectively), mainly after MVA vaccinations, and was sustained until week 52. HIV-specific CD8+ T cell responses increased significantly at week 30 in M/L and G/M (median change of 0.02 and 0.05%). Significant whole-blood gene expression changes were observed 2 wk after the first MVA injection, regardless of its use as prime or boost. An MVA gene signature was identified, including 86 genes mainly related to cell cycle pathways. Three prime-boost strategies led to CD4+ and CD8+ T cell responses and to a whole-blood gene expression signature primarily due to their MVA HIV-B component. | |
dc.language.iso | EN | en_US |
dc.title.en | T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial | |
dc.type | Article de revue | en_US |
dc.identifier.doi | 10.4049/jimmunol.2101076 | en_US |
dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
dc.identifier.pubmed | 35613727 | en_US |
bordeaux.journal | Journal of Immunology | en_US |
bordeaux.page | 2663-2674 | en_US |
bordeaux.volume | 208 | en_US |
bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
bordeaux.issue | 12 | en_US |
bordeaux.institution | Université de Bordeaux | en_US |
bordeaux.institution | INSERM | en_US |
bordeaux.institution | INRIA | |
bordeaux.team | SISTM_BPH | en_US |
bordeaux.peerReviewed | oui | en_US |
bordeaux.inpress | non | en_US |
hal.export | false | |
dc.rights.cc | Pas de Licence CC | en_US |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Immunology&rft.date=2022-06-15&rft.volume=208&rft.issue=12&rft.spage=2663-2674&rft.epage=2663-2674&rft.eissn=0022-1767&rft.issn=0022-1767&rft.au=RICHERT,%20Laura&LELIEVRE,%20Jean%20Daniel&LACABARATZ,%20Christine&HARDEL,%20Lucile&HOCINI,%20Hakim&rft.genre=article |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |